# Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

> **NCT05062980** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genprex, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** quaratusugene ozeplasmid
- **DRUG:** pembrolizumab
- **DRUG:** docetaxel
- **DRUG:** ramucirumab
- **DRUG:** Investigator's Treatment of Choice

## Key facts

- **NCT ID:** NCT05062980
- **Lead sponsor:** Genprex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-30
- **Primary completion:** 2025-02-03
- **Final completion:** 2025-02-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Enrollment was slow, due to competition with the many other clinical trials for the same patient population, which led to the decision to end enrollment in the trial.
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062980, "Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05062980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*